Here, we aim to investigate the effects of MEN1611 in models of NSCLC devoid of PIK3CA gene mutations and with EGFR activating mutations due to Exon19 deletion (Δ E746-A750) that are sensitive (HCC827) and resistant (RA1, RA2, RB1, RB1.1, and RB2) to EGFR-TKIs (erlotinib and gefitinib). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.